Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: A report of the pediatric oncology group randomized controlled trial 9233/34

Neuro-Oncology

Volumn 16, Issue 3, 2014, Pages 457-465

  Strother, Douglas R ^a   Lafay Cousin, Lucie ^a   Boyett, James M ^b   Burger, Peter ^c   Aronin, Patricia ^d   Constine, Louis ^e   Duffner, Patricia ^f   Kocak, Mehmet ^g   Kun, Larry E ^b   Horowitz, Marc E ^h   Gajjar, Amar ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d DELL INC   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TENNESSEE   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

brain tumors; chemotherapy; dose intensive; infants

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; VINCRISTINE;

ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; DEATH; EPENDYMOMA; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANCY; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; OVERALL SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

BRAIN TUMORS; CHEMOTHERAPY; DOSE-INTENSIVE; INFANTS;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; SUPRATENTORIAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84894272798     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not163     Document Type: Article

References (21)

1. Duffner PK, HorowitzME, Krischer JP, et al. Postoperativechemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328(24):1725-1731.
2. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J AmStat Assoc. 1958;53:457-481.
3. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important advances in oncology. Philadelphia: JB Lippincott, 1988:121-141.
4. Hryniuk WM. More is better. J Clin Oncol. 1988;6(9):1365-1367.
5. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer. 1996; 78(10):2127-2135.
6. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991;83(20):1460-1470.
7. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991;9(6):1050-1058.
8. Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6(8):573-580.
9. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23(30): 7621-7631.
10. Dhall G, GrodmanH, Ji L, et al.Outcomeof childrenlessthan threeyears old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer. 2008;50(6):1169-1175.
11. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978-986.
12. Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007; 8(8):696-705.
13. Grill J, Le Deley MC, Gambarelli D, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol. 2001;19(5):1288-1296.
14. Godfraind C, KaczmarskaJM, KocakM, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol. 2012;124(2):247-257.
15. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011;20(2):143-157.
16. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012; 123(4):465-472.
17. Lafay-Cousin L, Strother D. Current treatment approaches for infants with malignant central nervous system tumors. Oncologist. 2009; 14(4):433-444.
18. Van Poppel M, Klimo P Jr., Dewire M, et al. Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience. J Neurosurg Pediatr. 2011;8(3):251-256.
19. Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999;1(2): 152-161.
20. Sanders RP, Kocak M, Burger PC, Merchant TE, Gajjar A, Broniscer A. High-grade astrocytoma in very young children. Pediatr Blood Cancer. 2007;49(7):888-893.
21. Grundy RG, Wilne SH, Robinson KJ, et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer. 2010;46(1):120-133.